<DOC>
	<DOCNO>NCT00889798</DOCNO>
	<brief_summary>The purpose registry record information therapy reality malignant lymphatic systemic disease office-based haematologist Germany .</brief_summary>
	<brief_title>Tumor Registry Lymphatic Neoplasia</brief_title>
	<detailed_description>The TLN prospective , longitudinal , nation wide cohort study purpose record information antineoplastic treatment lymphatic neoplasm Germany . The registry follow patient five year . It identify common therapeutic sequence change treatment disease . At inclusion , data patient characteristic , comorbidities , tumor characteristic previous treatment collect . During course observation data systemic treatment , radiotherapy , surgery , outcome document . The impact nutrition ( LyNut ) physical activity ( LyNut ) course adjuvant disease examine patient indolent aggressive Non-Hodgin Lymphoma , well long-term effect systemic treatment ( LyTox ) quality life ( LyLife ) patient multiple myeloma .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<criteria>Confirmed diagnosis NonHodgkin ` lymphoma , chronic lymphocytic leukaemia multiple myeloma Must receive first secondline therapy 18 year old Signed , write informed consent systemic therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Malignant lymphatic disease</keyword>
	<keyword>therapy-reality</keyword>
	<keyword>observation</keyword>
	<keyword>registry</keyword>
	<keyword>therapy sequence</keyword>
	<keyword>NHL</keyword>
	<keyword>CLL</keyword>
	<keyword>Germany</keyword>
	<keyword>lenalidomide</keyword>
	<keyword>alemtuzumab</keyword>
	<keyword>rituximab</keyword>
	<keyword>bendamustin</keyword>
	<keyword>thalidomide</keyword>
	<keyword>bortezomib</keyword>
	<keyword>ibritumomab-tiuxetan</keyword>
	<keyword>G-CSF</keyword>
	<keyword>chronic lymphocytic leukaemia</keyword>
	<keyword>follicular lymphoma</keyword>
	<keyword>gastric MALT lymphoma</keyword>
	<keyword>nongastric MALT lymphoma</keyword>
	<keyword>nodal marginal zone lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
	<keyword>mantle cell lymphoma</keyword>
	<keyword>diffuse large b-cell lymphoma</keyword>
</DOC>